Androgen deprivation therapy (ADT) improves outcomes in men undergoing definitive radiotherapy for prostate cancer but carries significant toxicities. Clinical parameters alone are insufficient to accurately identify patients who will derive the most benefit, highlighting the need for improved patient selection tools to minimize unnecessary exposure to ADT's side effects while ensuring optimal oncological outcomes. The ArteraAI Prostate Test, incorporating a multimodal artificial intelligence (MMAI)-driven digital histopathology-based biomarker, offers prognostic and predictive information to aid in this selection. However, its clinical utility in real-world settings has yet to be measured prospectively.
This multicentre implementation trial aims to collect real-world data on the use of the previously validated Artera MMAI-driven prognostic and predictive biomarkers in men with intermediate-risk prostate cancer undergoing curative radiotherapy. The prognostic biomarker estimates the 10-year risk of metastasis, while the predictive biomarker determines the likely benefit from short-term ADT (ST-ADT). A total of 800 participants considering ST-ADT in conjunction with curative radiotherapy will be recruited from multiple Australian centers. Eligible patients with intermediate-risk prostate cancer, as defined by the National Comprehensive Cancer Network, will be asked to participate. The primary endpoint is the percentage of patients for whom testing led to a change in the shared ST-ADT recommendation, analyzed using descriptive statistics and McNemar's test comparing recommendations before and after biomarker testing. Secondary endpoints include the impact on quality of life and 5-year disease control, assessed through linkage with the Prostate Cancer Outcomes Registry. The sample size will be re-evaluated at an interim analysis after 200 patients.
ASTuTE will determine the impact of a novel prognostic and predictive biomarker on shared decision-making in the short term, and both quality of life and disease control in the medium term. If the biomarker demonstrates a significant impact on treatment decisions, it could lead to more personalized treatment strategies for men with intermediate-risk prostate cancer, potentially reducing overtreatment and improving quality of life. A potential limitation is the variability in clinical practice across different centers inherent in real-world studies.
Australian New Zealand Clinical Trials Registry, ACTRN12623000713695p. Registered 5 July 2023.
BMC cancer. 2025 Feb 13*** epublish ***
Eric Wegener, Michael Ng, Mario Guerrieri, Timothy N Showalter, Jeremy de Leon, Sagar Ramani, Marcus Dreosti, Tee Lim, Bradley Wong, Michael Chao, Kathryn Hogan, Avi Raman, Scott McClintock, Darren Foreman, Matthew Brown, Stephen McCombie, Kevin McMillan, Kieran Beattie, Mark Frydenberg, Lih-Ming Wong, Dickon Hayne, John Yaxley, Phillip Stricker, Jarad Martin
GenesisCare Lake Macquarie Private Hospital, 3 Sydney St Lake Macquarie, Gateshead, NSW, 2290, Australia. ., GenesisCare St Vincent's Hospital, 41 Victoria Parade, Fitzroy, VIC, 3065, Australia., Department of Radiation Oncology, University of Virginia, Charlottesville, Virginia, USA., GenesisCare St Vincent's Hospital, Level A, 438 Victoria Street, Darlinghurst, NSW, 2010, Australia., GenesisCare John Flynn Private Hospital, 42 Inland Drive, Tugun, QLD, 4224, Australia., Tennyson Centre, GenesisCare Kurralta Park, 520 South Road, Kurralta Park, SA, 5037, Australia., GenesisCare Fiona Stanley Hospital, 102-118 Murdoch Drive, Murdoch, WA, 6150, Australia., GenesisCare Buderim, 10 King Street, Buderim, QLD, 4556, Australia., GenesisCare Ringwood Private Hospital, 36 Mount Dandenong Road, Ringwood East, VIC, 3135, Australia., Lingard Specialist Centre, Suite 3/2 Lingard St, Merewether, NSW, 2291, Australia., Gold Coast Private Hospital, Level 3, 123 Nerang St, Southport, QLD, 4215, Australia., South Terrace Urology, 326 South Tce, Adelaide, SA, 5000, Australia., St John of God Wexford Medical Centre, 3 Barry Marshall Parade, Murdoch, 6150, WA, Australia., Knox Private Hospital, 262 Mountain Hwy, Wantirna, VIC, 3152, Australia., Suite 6, Maitland Specialist Centre, 173 Chisholm Rd, East Maitland, NSW, 2323, Australia., Australian Urology Associates, Ground Floor, 322 Glenferrie Rd, Malvern, VIC, 3144, Australia., Melbourne Urology Group, Suite 2, 141 Grey Street, East Melbourne, Australia., Medical School, The University of Western Australia, Perth, Australia., Wesley Urology Clinic, Suite 42, Level 4, Wesley Medical Centre, 40 Chasely Street, Auchenflower, QLD, 4066, Australia., St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia., GenesisCare Lake Macquarie Private Hospital, 3 Sydney St Lake Macquarie, Gateshead, NSW, 2290, Australia.